Durvalumab for Extensive-Stage of Small-Cell Lung Cancer With Lambert-Eaton Myasthenic Syndrome

Durvalumab is an immune checkpoint inhibitor (ICI) of anti-programmed cell death protein 1 ligand antibody. ICI-combined chemotherapy has recently become a standard regimen for extensive-stage of small-cell lung cancer (ES-SCLC). SCLC is well known to be the most likely tumor associated with Lambert...

Descripción completa

Detalles Bibliográficos
Autores principales: Machiyama, Hirotomo, Minami, Seigo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elmer Press 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9990708/
https://www.ncbi.nlm.nih.gov/pubmed/36896371
http://dx.doi.org/10.14740/jmc4043

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9990708/
https://www.ncbi.nlm.nih.gov/pubmed/36896371
http://dx.doi.org/10.14740/jmc4043

Ejemplares similares